Tetratherix (ASX:TTX) said its Tutelix joint venture received ethics committee approval to launch a clinical trial for hydrogel spacer in Australia, according to a Tuesday filing with the Australian bourse.

The Tutelix hydrogel spacer is used during cancer treatments to protect healthy parts of the body from damage.

Positive six-month follow-up data confirms an opportunity for the product beyond the prostate cancer program, providing the company with a technical basis to pursue a gynaecological cancer indication, Tetratherix Chief Technology Officer Ali Fathi said.

The clinical study has completed enrolment of all 15 patients across multiple Australian sites, per the filing.